139308-65-9
Chemical Structure
Tolafentrine
- CAS No.: 139308-65-9
- Formula:C28H31N3O4S
- Molecular Weight:505.63
IUPAC Name: N-(4-((4aS,10bR)-8,9-dimethoxy-2-methyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridin-6-yl)phenyl)-4-methylbenzenesulfonamide
InChIKey: FVZJIAUYFDQQKJ-DQEYMECFSA-N
SMILES: [H][C@@]12CN(CC[C@@]1(N=C(C3=C2C=C(C(OC)=C3)OC)C4=CC=C(C=C4)NS(C5=CC=C(C=C5)C)(=O)=O)[H])C
Biological Activity: Tolafentrine, a dual-selective phosphodiesterase 3/4 (PDE3/4) inhibitor, has been shown to have significant acute and chronic effects in a unilateral diacetamide-induced rat pulmonary hypertension model. Experiments show that long-term administration can significantly alleviate all unilateral bisacetamide-induced hemodynamic and gas exchange abnormalities, reduce right ventricular hypertrophy, and normalize pulmonary vascular remodeling changes[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tolafentrine | Tolafentrine, a dual-selective phosphodiesterase 3/4 (PDE3/4) inhibitor, has been shown to have significant acute and chronic effects in a unilateral diacetamide-induced rat pulmonary hypertension model. Experiments show that long-term administration can significantly alleviate all unilateral bisacetamide-induced hemodynamic and gas exchange abnormalities, reduce right ventricular hypertrophy, and normalize pulmonary vascular remodeling changes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
